All stocks / CERO
CERO THERAPEUTICS HOLDINGS, INC. CERO
CERO Therapeutics Holdings (CERO): shares outstanding up 295% in a year, convertible notes mentioned in an 8-K in May 2026, a late 10-K notice in April 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- CERO THERAPEUTICS HOLDINGS INC
- Market tier
- OTCQB
- Trading status
- Active
- Last trade
- Nov 16
- Website
- www.cero.bio
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Net loss
- ($19,920,262)
It spends more than it earns
Under strainThe company lost $19.9 million in the year. It reported no sales.
- Cash and cash equivalents
- $1,700,000
- Net cash used in operating activities
- ($16,100,000)
The cash could run out soon
Under strainIt had $1.7 million in the bank and used about $1.3 million a month. At that pace the money lasts about 1 months unless it borrows or sells more shares.
- Total assets
- $3,641,134
- Total liabilities
- $9,087,596
It owes more than it owns
Under strainEverything the company owns adds up to $3.6 million. Its debts and unpaid bills add up to $9.1 million. That is about $2.50 owed for every $1 owned.
What this adds up to
3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.
Signals
Shares outstanding rose from 21,102,671 (2025-11-19) to 83,309,742 (2026-11-13), up 295%.
Rule: Shares outstanding up 20% or more in 12 months. Source record
Estimated float about 83,309,742 shares as of 2026-11-13: 83,309,742 outstanding minus 0 held by 0 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
8-K filed 2026-05-29 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2026-05-01 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2026-04-14 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Filed NT 10-K on 2026-04-01: notice that a periodic report is late.
Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record
8-K filed 2026-03-11 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2026-02-13 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
8-K filed 2025-12-02 mentions: equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Filed NT 10-Q on 2025-11-17: notice that a periodic report is late.
Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
| 2026-11-13 | 10-Q | QUARTERLY REPORT |
| 2026-10-07 | 8-K | CURRENT REPORT |
| 2026-08-31 | 8-K | CURRENT REPORT |
| 2026-08-14 | SCHEDULE 13G/A | |
| 2026-08-14 | 10-Q | QUARTERLY REPORT |
| 2026-08-14 | 424B3 | PROSPECTUS SUPPLEMENT |
| 2026-07-17 | 8-K | CURRENT REPORT |
| 2026-07-17 | 424B3 | PROSPECTUS SUPPLEMENT |
| 2026-07-13 | 25-NSE | |
| 2026-06-26 | 8-K | CURRENT REPORT |
| 2026-06-26 | 424B3 | PROSPECTUS SUPPLEMENT |
| 2026-05-29 | 8-K | CURRENT REPORT |
Common questions about CERO
Does CERO file reports with the SEC?
Yes. CERO Therapeutics Holdings files with the SEC under company number 0001870404. The most recent filing we hold is a 10-Q dated 2026-11-13.
Source recordHow many CERO shares are outstanding?
83,309,742 shares as of 2026-11-13, as reported to the SEC. That is up 295% from 21,102,671 on 2025-11-19.
Source recordHas CERO filed reports late?
Yes. In the last 12 months it filed 2 late-filing notices, most recently a NT 10-K on 2026-04-01. A notice means a report was not ready on time; check whether the report followed.
Source recordWho runs CERO Therapeutics Holdings?
Officers named in its insider filings: Christopher B Ehrlich (Chairman and CEO), Andrew Albert Kucharchuk (Chief Financial Officer) and Kristen Pierce (Chief Development Officer).
Source recordIs CERO Therapeutics Holdings making money?
The company lost $19.9 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record